Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 6, 2007

Epix Achieves Milestone for Second Discovery Program in GSK Partnership

  • Epix Pharmaceuticals received $3 million for its identification of three candidates to move forward into lead optimization in the GPCR discovery alliance with GlaxoSmithKline (GSK). This marks the second of three discovery programs embarked upon under the collaboration inked in December 2006.

    As part of the agreement, GSK initially paid $35 million including $17.5 million through the purchase of its common stock. Epix received its first $3 million milestone payment in August and stands to make up to $1.194 billion in future achievement-based fees. The company is also entitled to receive tiered double-digit royalties on sales by GSK of all collaboration-developed products.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »